Global Skin Boosters Market Strategic Research Report 2026-2031

Publication ID:

NAV1026017

Publication Date:

October 20, 2026

Pages:

219

Countries:

Global [1]

The global skin boosters market is estimated at approximately USD 1,374 million in 2025 and is projected to reach USD 3,046 million by 2031, a compound annual growth rate (CAGR) of 14.3% over 2026–2031 (14.2% over 2025–2031). Asia Pacific is the largest region at about 55% of 2025 value and the fastest-growing at about 16.2% a year; Europe follows at about 24% and North America at about 12%. Values are analyst estimates built bottom-up, because no company reports skin booster sales as a separate line; every estimate carries its stated method and reason, and verified company and regulatory data are disclosed where available.

A skin booster is an injectable placed into or just under the skin and sold through licensed practitioners to improve skin quality (hydration, elasticity, texture and tone), not to restore volume. The report covers hyaluronic acid (HA), polynucleotide and polydeoxyribonucleotide (PN/PDRN), poly-L-lactic acid and poly-DL-lactic acid (PLLA/PDLLA), recombinant collagen, diluted calcium hydroxylapatite (CaHA) and other injectable boosters (polycaprolactone-based and combination products). Volumising fillers, botulinum toxin, topical products, raw-material and cosmetic-ingredient sales, PRP and unregistered products are excluded. Bear and bull cases are USD 2,627 million (11.4% CAGR) and USD 3,519 million (17.0% CAGR) by 2031.

Verified market context

SKINVIVE by Juvederm received US FDA approval on 15 May 2023 for improving skin smoothness of the cheeks, the first HA intradermal microdroplet injection in the US.
A leading global filler maker reported fillers and biostimulators sales of USD 1,101 million in 2025, up 8.0%, with biostimulators growing double digits.
A leading Chinese HA injectable maker reported 2025 revenue of RMB 2,453 million, down 18.94%, as approved competing products multiplied.
A leading Korean PN maker reported first-quarter 2026 revenue of KRW 146.1 billion, with exports about 40% of revenue.
A recombinant humanised type III collagen injection was approved in China in October 2023.
Profhilo has been licensed for the US, with commercialisation planned for 2030.

Scope of the Global Skin Boosters Market Strategic Research Report 2026-2031

This report provides market sizing in value (USD million) and 2026–2031 forecasts, with 2025 as the base year, by ingredient type, application, region and country. It includes a regional outlook across 5 regions and 25 country lines including China, South Korea, the United States and Europe, growth drivers and inhibitors, a competitive landscape, Porter's Five Forces, PESTLE and SWOT analysis, future trends, and profiles of 12 key companies.

Segment by Type

Hyaluronic Acid (HA) Skin Boosters
Polynucleotide (PN/PDRN) Skin Boosters
Poly-L-Lactic Acid (PLLA) and Poly-DL-Lactic Acid (PDLLA) Skin Boosters
Recombinant Collagen Skin Boosters
Diluted Calcium Hydroxylapatite (CaHA) Skin Boosters
Other Injectable Skin Boosters (Polycaprolactone-Based and Combination Products)

Segment by Application

Dermatology Clinics
Medspas and Aesthetic Clinics
Hospitals and Other Settings

Key Companies Profiled

Galderma, AbbVie (Allergan Aesthetics), PharmaResearch Co., Ltd., Imeik Technology Development Co., Ltd., Bloomage Biotechnology Corporation Limited, Medytox Inc., Merz Aesthetics, Huadong Medicine Co., Ltd., IBSA Group, Evolus, Inc., Dexlevo Co., Ltd., Shanxi Jinbo Bio-Pharmaceutical Co., Ltd..

Who Can Use This Report?

Aesthetic injectable manufacturers and licensors, distributors and clinic groups, investors and corporate development teams, regulatory and market-access teams planning China, Korea, US and European filings, and consultants who need a defined, sourced view of the skin booster market.

1. Executive Summary
1.1 Market Definition and Scope
1.2 Headline Market Size and Growth Trajectory
1.3 Principal Growth Drivers
1.4 Segment Highlights
1.5 Regional and Country Highlights
1.6 Competitive Structure and Key Corporate Developments
1.7 Principal Risks to the Outlook
1.8 Closing Outlook
2. Industry Overview & Forecast
    2.1.1 Market Definition and Scope
    2.1.2 Market Size and Historical Performance
    2.1.3 Forecast and Growth Logic
    2.1.4 Volume and Procedure Context
    2.1.5 Value Chain and Pricing Considerations
3. Market Segmentation by Type
3.1 Overview of the Ingredient Landscape
    3.1.1 Hyaluronic Acid Skin Boosters
    3.1.2 Polynucleotide (PN/PDRN) Skin Boosters
    3.1.3 Poly-L-Lactic Acid (PLLA) and Poly-DL-Lactic Acid (PDLLA) Skin Boosters
    3.1.4 Recombinant Collagen Skin Boosters
    3.1.5 Diluted Calcium Hydroxylapatite (CaHA) Skin Boosters
    3.1.6 Other Injectable Skin Boosters (Polycaprolactone-Based and Combination Products)
3.2 Comparative Mix Shift and Segment Trajectory
4. Market Segmentation by Application
4.1 Overview and Structural Framework
    4.1.1 Dermatology Clinics
    4.1.2 Medspas and Aesthetic Clinics
    4.1.3 Hospitals and Other Settings
    4.1.4 Comparative Assessment of Application Segments
5. Regional Market Forecast
5.1 North America
    5.1.1 Regional Overview
    5.1.2 Key Growth Drivers
    5.1.3 Regulatory & Infrastructure Landscape
    5.1.4 Country-Level Analysis
    5.1.5 Market Forecast 2025–2031
5.2 Europe
    5.2.1 Regional Overview
    5.2.2 Key Growth Drivers
    5.2.3 Regulatory & Infrastructure Landscape
    5.2.4 Country-Level Analysis
    5.2.5 Market Forecast 2025–2031
5.3 Asia Pacific
    5.3.1 Regional Overview
    5.3.2 Key Growth Drivers
    5.3.3 Regulatory & Infrastructure Landscape
    5.3.4 Country-Level Analysis
    5.3.5 Market Forecast 2025–2031
5.4 Middle East and Africa
    5.4.1 Regional Overview
    5.4.2 Key Growth Drivers
    5.4.3 Regulatory & Infrastructure Landscape
    5.4.4 Country-Level Analysis
    5.4.5 Market Forecast 2025–2031
5.5 Latin America
    5.5.1 Regional Overview
    5.5.2 Key Growth Drivers
    5.5.3 Regulatory & Infrastructure Landscape
    5.5.4 Country-Level Analysis
    5.5.5 Market Forecast 2025–2031
6. Country-Level Market Forecast
6.1 North America
    6.1.1 United States
    6.1.2 Canada
    6.1.3 Mexico
    6.1.4 Rest of North America
6.2 Europe
    6.2.1 Germany
    6.2.2 France
    6.2.3 United Kingdom
    6.2.4 Italy
    6.2.5 Russia
    6.2.6 Rest of Europe
6.3 Asia Pacific
    6.3.1 China
    6.3.2 Japan
    6.3.3 South Korea
    6.3.4 Southeast Asia
    6.3.5 India
    6.3.6 Australia
    6.3.7 Rest of Asia Pacific
6.4 Middle East and Africa
    6.4.1 Egypt
    6.4.2 South Africa
    6.4.3 Israel
    6.4.4 Turkey
    6.4.5 GCC Countries
    6.4.6 Rest of Middle East and Africa
6.5 Latin America
    6.5.1 Brazil
    6.5.2 Rest of Latin America
7. Growth Drivers & Inhibitors
7.1 Growth Drivers
    7.1.1 Rising Practitioner Demand and Medspa Channel Proliferation
    7.1.2 Regulatory Approvals Unlocking New Country-Level Markets
    7.1.3 Ingredient Innovation and Portfolio Differentiation
    7.1.4 Anti-Ageing Demographic Momentum and Premiumisation of Skin Health
    7.1.5 Growing Scientific Validation and Clinical Evidence Accumulation
    7.1.6 Asia Pacific Market Deepening and South Korean Export Expansion
7.2 Growth Inhibitors
    7.2.1 Price Compression in the Chinese Market Following Product Proliferation
    7.2.2 Absence of US Regulatory Approval for Polynucleotide Injectables
    7.2.3 Grey-Market Products Distorting Market Integrity and Volume Visibility
    7.2.4 Thin Company Disclosure and Estimation Uncertainty Constraining Investment Confidence
    7.2.5 Regulatory Complexity and Classification Inconsistency Across Jurisdictions
7.3 Impact Assessment Summary
7.4 Integrated Force Assessment
8. Key Company Profiles
8.1 Galderma
    8.1.1 Company Overview
    8.1.2 Key Products & Segments
    8.1.3 Financial Performance (2023–2025)
    8.1.4 Business Strategy
    8.1.5 SWOT Analysis
    8.1.6 Strategic Implications (2025–2031)
8.2 AbbVie (Allergan Aesthetics)
    8.2.1 Company Overview
    8.2.2 Key Products & Segments
    8.2.3 Financial Performance (2023–2025)
    8.2.4 Business Strategy
    8.2.5 SWOT Analysis
    8.2.6 Strategic Implications (2025–2031)
8.3 PharmaResearch Co., Ltd.
    8.3.1 Company Overview
    8.3.2 Key Products & Segments
    8.3.3 Financial Performance (2023–2025)
    8.3.4 Business Strategy
    8.3.5 SWOT Analysis
    8.3.6 Strategic Implications (2025–2031)
8.4 Imeik Technology Development Co., Ltd.
    8.4.1 Company Overview
    8.4.2 Key Products & Segments
    8.4.3 Financial Performance (2023–2025)
    8.4.4 Business Strategy
    8.4.5 SWOT Analysis
    8.4.6 Strategic Implications (2025–2031)
8.5 Bloomage Biotechnology Corporation Limited
    8.5.1 Company Overview
    8.5.2 Key Products & Segments
    8.5.3 Financial Performance (2023–2025)
    8.5.4 Business Strategy
    8.5.5 SWOT Analysis
    8.5.6 Strategic Implications (2025–2031)
8.6 Medytox Inc.
    8.6.1 Company Overview
    8.6.2 Key Products & Segments
    8.6.3 Financial Performance (2023–2025)
    8.6.4 Business Strategy
    8.6.5 SWOT Analysis
    8.6.6 Strategic Implications (2025–2031)
8.7 Merz Aesthetics
    8.7.1 Company Overview
    8.7.2 Key Products & Segments
    8.7.3 Financial Performance (2023–2025)
    8.7.4 Business Strategy
    8.7.5 SWOT Analysis
    8.7.6 Strategic Implications (2025–2031)
8.8 Huadong Medicine Co., Ltd.
    8.8.1 Company Overview
    8.8.2 Key Products & Segments
    8.8.3 Financial Performance (2023–2025)
    8.8.4 Business Strategy
    8.8.5 SWOT Analysis
    8.8.6 Strategic Implications (2025–2031)
8.9 IBSA Group
    8.9.1 Company Overview
    8.9.2 Key Products & Segments
    8.9.3 Financial Performance (2023–2025)
    8.9.4 Business Strategy
    8.9.5 SWOT Analysis
    8.9.6 Strategic Implications (2025–2031)
8.10 Evolus, Inc.
    8.10.1 Company Overview
    8.10.2 Key Products & Segments
    8.10.3 Financial Performance (2023–2025)
    8.10.4 Business Strategy
    8.10.5 SWOT Analysis
    8.10.6 Strategic Implications (2025–2031)
8.11 Dexlevo Co., Ltd.
    8.11.1 Company Overview
    8.11.2 Key Products & Segments
    8.11.3 Financial Performance (2023–2025)
    8.11.4 Business Strategy
    8.11.5 SWOT Analysis
    8.11.6 Strategic Implications (2025–2031)
8.12 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd.
    8.12.1 Company Overview
    8.12.2 Key Products & Segments
    8.12.3 Financial Performance (2023–2025)
    8.12.4 Business Strategy
    8.12.5 SWOT Analysis
    8.12.6 Strategic Implications (2025–2031)
9. Competitive Landscape
9.1 Competitive Landscape Overview
    9.1.1 Market Concentration and Structure
    9.1.2 Leading Players and Disclosed Anchors (2025)
    9.1.3 Competitive Intensity and HHI Assessment
    9.1.4 Competitive Asymmetries by Geography
    9.1.5 Strategic Implications for Competitive Positioning
9.2 Competitive Intensity Assessment
    9.2.1 Tier Structure and Revenue Positioning
    9.2.2 Tier 1: Global Incumbent Dominance With Structural Blind Spots
    9.2.3 Tier 2: Regional Champions Driving Category Intensity
    9.2.4 Tier 3
    9.2.5 Pricing Environment: Premium, Value, and Emerging Commoditisation
    9.2.6 Barriers to Entry and Exit
9.3 Key Player Strategies & Positioning
    9.3.1 Strategic Group Map Narrative
    9.3.2 Differentiation Strategies Across Major Players
    9.3.3 Geographic Strongholds
    9.3.4 M&A and Partnership Activity, 2022–Present
    9.3.5 R&D and Technology Investment Trends
9.4 Competitive Dynamics & Strategic Outlook
    9.4.1 The Competitive Landscape in Context
    9.4.2 Emerging Competitive Threats
    9.4.3 Consolidation versus Fragmentation Outlook
    9.4.4 Competitive Response Matrix
    9.4.5 Strategic Recommendations for 2025–2031
    9.4.6 Conclusion
10. Porter's Five Forces Analysis
10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry
11. PESTLE Analysis
11.1 Political
11.2 Economic
11.3 Sociocultural
11.4 Technological
11.5 Legal
11.6 Environmental
11.7 PESTLE Summary Assessment Table
12. SWOT Analysis
    12.1.1 Detailed Analysis
      12.1.1.1 Strengths
      12.1.1.2 Weaknesses
      12.1.1.3 Opportunities
      12.1.1.4 Threats
    12.1.2 Strategic Implications
13. Future Trends & Outlook
13.1 Overview
13.2 Trend Analysis
    13.2.1 Polynucleotide Ascendancy Displacing Hyaluronic Acid as the High-Growth Standard of Care
    13.2.2 Recombinant Collagen Emerging as the Next Disruptive Ingredient Paradigm
    13.2.3 Asia Pacific's Structural Dominance and the South Korea-to-China Innovation Corridor
    13.2.4 North American Market Activation Through FDA Regulatory Milestones
    13.2.5 Biostimulator Convergence and the Blurring Boundary Between Skin Quality and Volumisation
    13.2.6 Medspa and Aesthetic Clinic Channel Ascendancy Reshaping Distribution Dynamics
    13.2.7 Price Compression in Mature Formulations and the Premium Positioning Imperative
    13.2.8 Geographic Expansion of PN Regulatory Approvals as a Near-Term Market Unlocking Event
13.3 Summary Trend Table
13.4 Forward Outlook

List of Exhibits
Exhibit 2.1: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
Exhibit 2.2: Forecast of Global (in USD Bn)
Exhibit 2.3: Forecast of North America (in USD Bn)
Exhibit 2.4: Forecast of Europe (in USD Bn)
Exhibit 2.5: Forecast of Asia Pacific (in USD Bn)
Exhibit 2.6: Forecast of Middle East and Africa (in USD Bn)
Exhibit 2.7: Forecast of Latin America (in USD Bn)
Exhibit 3.8: Forecast of Hyaluronic Acid (HA) Skin Boosters (in USD Bn)
Exhibit 3.9: Forecast of Polynucleotide (PN/PDRN) Skin Boosters (in USD Bn)
Exhibit 3.10: Forecast of Recombinant Collagen Skin Boosters (in USD Bn)
Exhibit 3.11: Forecast of Diluted Calcium Hydroxylapatite (CaHA) Skin Boosters (in USD Bn)
Exhibit 3.12: Forecast of Segment Type (in USD Bn)
Exhibit 3.13: Forecast of Segment Type (in USD Bn)
Exhibit 4.14: Forecast of Dermatology Clinics (in USD Bn)
Exhibit 4.15: Forecast of Medspas and Aesthetic Clinics (in USD Bn)
Exhibit 4.16: Forecast of Hospitals and Other Settings (in USD Bn)
Exhibit 6.17: Forecast of North America (in USD Bn)
Exhibit 6.18: Forecast of United States (in USD Bn)
Exhibit 6.19: Forecast of Europe (in USD Bn)
Exhibit 6.20: Forecast of Germany (in USD Bn)
Exhibit 6.21: Forecast of France (in USD Bn)
Exhibit 6.22: Forecast of United Kingdom (in USD Bn)
Exhibit 6.23: Forecast of Italy (in USD Bn)
Exhibit 6.24: Forecast of Rest of Europe (in USD Bn)
Exhibit 6.25: Forecast of Asia Pacific (in USD Bn)
Exhibit 6.26: Forecast of China (in USD Bn)
Exhibit 6.27: Forecast of Japan (in USD Bn)
Exhibit 6.28: Forecast of South Korea (in USD Bn)
Exhibit 6.29: Forecast of Southeast Asia (in USD Bn)
Exhibit 6.30: Forecast of Australia (in USD Bn)
Exhibit 6.31: Forecast of Middle East and Africa (in USD Bn)
Exhibit 6.32: Forecast of Latin America (in USD Bn)
Exhibit 6.33: Forecast of Brazil (in USD Bn)
Exhibit 6.34: Forecast of Rest of Latin America (in USD Bn)

Galderma
AbbVie (Allergan Aesthetics)
PharmaResearch Co. Ltd.
Imeik Technology Development Co. Ltd.
Bloomage Biotechnology Corporation Limited
Medytox Inc.
Merz Aesthetics
Huadong Medicine Co. Ltd.
IBSA Group
Evolus Inc.
Dexlevo Co. Ltd.
Shanxi Jinbo Bio-Pharmaceutical Co. Ltd.

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.